These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

340 related items for PubMed ID: 23644210

  • 21. Discovery of potent HDAC inhibitors based on chlamydocin with inhibitory effects on cell migration.
    Wang S, Li X, Wei Y, Xiu Z, Nishino N.
    ChemMedChem; 2014 Mar; 9(3):627-37. PubMed ID: 24285590
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Identification of a series of substituted 2-piperazinyl-5-pyrimidylhydroxamic acids as potent histone deacetylase inhibitors.
    Angibaud P, Van Emelen K, Decrane L, van Brandt S, Ten Holte P, Pilatte I, Roux B, Poncelet V, Speybrouck D, Queguiner L, Gaurrand S, Mariën A, Floren W, Janssen L, Verdonck M, van Dun J, van Gompel J, Gilissen R, Mackie C, Du Jardin M, Peeters J, Noppe M, Van Hijfte L, Freyne E, Page M, Janicot M, Arts J.
    Bioorg Med Chem Lett; 2010 Jan 01; 20(1):294-8. PubMed ID: 19906529
    [Abstract] [Full Text] [Related]

  • 24. Synthesis and antitumor activity of novel diaryl ether hydroxamic acids derivatives as potential HDAC inhibitors.
    Zhu Y, Chen X, Wu Z, Zheng Y, Chen Y, Tang W, Lu T.
    Arch Pharm Res; 2012 Oct 01; 35(10):1723-32. PubMed ID: 23139122
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Design, synthesis and preliminary biological evaluation of N-hydroxy-4-(3-phenylpropanamido)benzamide (HPPB) derivatives as novel histone deacetylase inhibitors.
    Jiao J, Fang H, Wang X, Guan P, Yuan Y, Xu W.
    Eur J Med Chem; 2009 Nov 01; 44(11):4470-6. PubMed ID: 19608304
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Design, synthesis and biological evaluation of tyrosine-based hydroxamic acid analogs as novel histone deacetylases (HDACs) inhibitors.
    Zhang Y, Feng J, Liu C, Fang H, Xu W.
    Bioorg Med Chem; 2011 Aug 01; 19(15):4437-44. PubMed ID: 21733698
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Design, synthesis and antiproliferative activities of novel benzamides derivatives as HDAC inhibitors.
    Li Y, Wang Y, Xie N, Xu M, Qian P, Zhao Y, Li S.
    Eur J Med Chem; 2015 Jul 15; 100():270-6. PubMed ID: 26140961
    [Abstract] [Full Text] [Related]

  • 34. Design, synthesis and biological evaluation of β-boswellic acid based HDAC inhibitors as inducers of cancer cell death.
    Sharma S, Ahmad M, Bhat JA, Kumar A, Kumar M, Zargar MA, Hamid A, Shah BA.
    Bioorg Med Chem Lett; 2014 Oct 01; 24(19):4729-4734. PubMed ID: 25176189
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Development of 3-hydroxycinnamamide-based HDAC inhibitors with potent in vitro and in vivo anti-tumor activity.
    Li X, Hou J, Li X, Jiang Y, Liu X, Mu W, Jin Y, Zhang Y, Xu W.
    Eur J Med Chem; 2015 Jan 07; 89():628-37. PubMed ID: 25462271
    [Abstract] [Full Text] [Related]

  • 38. Design, synthesis and docking studies on benzamide derivatives as histone deacetylase inhibitors.
    Lu A, Luo H, Shi M, Wu G, Yuan Y, Liu J, Tang F.
    Bioorg Med Chem Lett; 2011 Aug 15; 21(16):4924-7. PubMed ID: 21741834
    [Abstract] [Full Text] [Related]

  • 39. Design, synthesis and biological evaluation of novel isoindolinone derivatives as potent histone deacetylase inhibitors.
    Chen X, Zhao S, Li H, Wang X, Geng A, Cui H, Lu T, Chen Y, Zhu Y.
    Eur J Med Chem; 2019 Apr 15; 168():110-122. PubMed ID: 30802729
    [Abstract] [Full Text] [Related]

  • 40. Discovery of 1,3-Disubstituted 2,5-Diketopiperazine Derivatives as Potent Class I HDACs Inhibitors.
    Gong G, Qi J, Lv Y, Dong S, Cao C, Li D, Zhao R, Li Z, Chen X.
    Chem Pharm Bull (Tokyo); 2020 Apr 15; 68(5):466-472. PubMed ID: 32378544
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.